Manufacturing

1. The Near-Term Future Of Exosome Science With Capricor Therapeutics' Dr. Linda Marbán 4/12/2023

   Dr. Linda Marbán, Ph.D., CEO of Capricor Therapeutics, a clinical-stage biotech focused on the development of cell and exosome-based therapeutics for the treatment and prevention of serious diseases, joins Cell & Gene: The Podcast's Erin Harris to discuss the current state and the near-term future of exosomes. Marbán discusses Capricor’s exosome program and the company’s proprietary allogeneic cardiosphere-derived cells (CDCs) and engineered exosomes. She also covers the company's HOPE clinical trial series' progress to treat Duchenne muscular dystrophy (DMD).

2. Harnessing AI and Synthetic Biology for Cell Therapies with Generate:Biomedicines' Dr. Alex Snyder 5/20/2025

   Host Erin Harris talks to Generate:Biomedicines' EVP of R&D, Dr. Alex Snyder on Cell & Gene: The Podcast about the convergence of AI, machine learning (ML), and synthetic biology in the development of next-generation therapies. They cover how AI is transforming drug discovery by enabling the rapid design and optimization of therapeutic candidates, particularly in complex fields like immuno-oncology and cell therapy.

3. 4 Keys To Allo In 2024 With Poseida Therapeutics' Kristin Yarema, Ph.D. 1/2/2024

   Kristin Yarema, Ph.D., CEO, Poseida Therapeutics sits down with Cell & Gene: The Podcast Host Erin Harris to discuss four of the biggest challenges the CGT sector faces when it comes to the development of off-the-shelf therapies. Kristin shares how 2024 might see some real progress in allogeneic therapies. 

4. The Why Behind In-House Manufacturing With Sangamo's Andy Ramelmeier 2/13/2023

   On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Andy Ramelmeier, EVP Head of Technical Operations at Sangamo Therapeutics, a biotech based in Brisbane, California that applies cell and gene therapy to combat Hemophilia A and other genetic diseases. Ramelmeier explains the why behind the company's decision to build its own Phase 1/2 cGMP AAV in-house facility. He also talks broadly about manufacturing cell and gene therapies and the potential and realistic solutions to needed to drive down manufacturing costs.

5. Commercialization Learnings With Novartis Gene Therapies' President Chris Fox 9/7/2022

   With 20+ gene therapy targets in Novartis Gene Therapies’ pipeline, President Chris Fox and her team are hyper-focused on newborn screenings as the pathway to helping more and more patients. The company's initial gene therapy, Zolgensma, for spinal muscular atrophy (SMA) has been approved in more than 40 regions and countries and has been used to treat more than 2,300 patients worldwide. Fox details what’s next on the commercialization front for the therapy, and she shares advice with Cell & Gene: The Podcast listeners about what it takes to commercialize a therapy,

6. The Promise Of Genome Editing With Caribou Biosciences' Rachel Haurwitz, Ph.D. 8/15/2023

   On this episode of Cell & Gene: The Podcast, Rachel Haurwitz, Ph.D., CEO at Caribou Biosciences joins Host Erin Harris to discuss the evolution of genome editing, its present state, as well as its undeniable potential. Listen now to learn more about Caribou's chRDNA genome editing technology and how it differs from CRISPR-Cas9.

7. The Future Of Cell And Organ Transplantation In Treating T1D With Dr. Camillo Ricordi 10/10/2023

   Explore the biggest and most troubling challenges facing the treatment of Type 1 Diabetes (T1D) and the future of cell and organ transplantation in treating T1D as well as the latest innovations in biopreservation.

8. Overcoming The Limitations Of CAR T-Cell Therapy With Vittoria Bio's Nick Siciliano, Ph.D. 12/5/2023

   Vittoria Biotherapeutics’ CEO, Nick Siciliano, joins Erin Harris on this episode of Cell & Gene: The Podcast to discuss the company's mission to expand the applications for CAR-based therapeutics by employing novel cell engineering and gene editing technologies.

9. The Future Of CAR-T With Bristol Myers Squibb's Lynelle Hoch 8/25/2023

   Check out a discussion on the near-term future of CAR-T, along with a deep dive into various innovations and patient access progress being made in both solid tumors and hematologic malignancies.

10. Planning For Manufacturing Capacity With Kite Pharma's Will Junker 9/26/2022

    Will Junker, Head of Manufacturing Quality at Kite Pharma, talks to Cell & Gene: The Podcast listeners about the challenges associated with capacity planning, whether to partner with a CDMO, and why it's important to prioritize inventory over time-to-market. We also discuss why developing a better understanding of the vector manufacturing process is critical to bringing continuous and secure supply to market.